The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Milton Packer, M.D., Michael R. Bristow, M.D., Ph.D., Jay N. Cohn, M.D., Wilson S. Colucci, M.D., Michael B. Fowler, M.B., B.S., Edward M. Gilbert, M.D., Neil H. Shusterman, M.D., for The U.S. Carvedilol Heart Failure Study Group
Background Controlled clinical trials have shown that beta-blockerscan produce hemodynamic and symptomatic improvement in chronicheart failure, but the effect of these drugs on survival hasnot been determined.
Methods We enrolled 1094 patients with chronic heart failurein a double-blind, placebo-controlled, stratified program, inwhich patients were assigned to one of four treatment protocolson the basis of their exercise capacity. Within each of thefour protocols patients with mild, moderate, or severe heartfailure with left ventricular ejection fractions 0.35 were randomlyassigned to receive either placebo (n = 398) or the beta-blockercarvedilol (n = 696); background therapy with digoxin, diuretics,and an angiotensin-converting–enzyme inhibitor remainedconstant. Patients were observed for the occurrence of deathor hospitalization for cardiovascular reasons during the following6 months (12 months for the group with mild heart failure).
Results The overall mortality rate was 7.8 percent in the placebogroup and 3.2 percent in the carvedilol group; the reductionin risk attributable to carvedilol was 65 percent (95 percentconfidence interval, 39 to 80 percent; P<0.001). This findingled the Data and Safety Monitoring Board to recommend terminationof the study before its scheduled completion. In addition, ascompared with placebo, carvedilol therapy was accompanied bya 27 percent reduction in the risk of hospitalization for cardiovascularcauses (19.6 percent vs. 14.1 percent, P = 0.036), as well asa 38 percent reduction in the combined risk of hospitalizationor death (24.6 percent vs. 15.8 percent, P<0.001). Worseningheart failure as an adverse reaction during treatment was lessfrequent in the carvedilol group than in the placebo group.
Conclusions Carvedilol reduces the risk of death as well asthe risk of hospitalization for cardiovascular causes in patientswith heart failure who are receiving treatment with digoxin,diuretics, and an angiotensin-converting–enzyme inhibitor.
Activation of the sympathetic nervous system is one of the cardinalpathophysiologic abnormalities in patients with chronic heartfailure. Levels of circulating catecholamines increase in patientswith heart failure in proportion to the severity of disease,1and those with the highest plasma levels of norepinephrine havethe most unfavorable prognosis.2 These observations have ledto the hypothesis that sympathetic activation plays an importantpart in the progression of heart failure.3,4 Norepinephrinecan exert adverse effects on the circulation, both directlyand indirectly,5,6 and interference with its actions can retardthe progression of heart failure in animal models of the disease.7,8
These findings have led investigators to propose that sympatheticantagonists (e.g., beta-blockers) might be useful in the managementof heart failure. Such drugs were previously considered to becontraindicated in this disorder because of their short-termadverse effects,9 but studies in Sweden in the 1970s raisedthe possibility that long-term therapy with these drugs mightproduce hemodynamic and clinical benefits.10,11 Controlled trialsof several different beta-blockers have shown that these drugscan reduce symptoms, improve left ventricular function, andincrease functional capacity,12,13,14,15,16,17,18 but recentlarge-scale studies19,20 have not clarified the effects of beta-blockerson morbidity and mortality in patients with heart failure.
Hence, when a large clinical trial program with carvedilol inheart failure was being designed in 1992, we prospectively definedan overall objective of the program to be an evaluation of theeffect of the drug on survival. Our principal goal was to assessthe safety of carvedilol while recognizing its potential toprolong life, demonstrated by the results of experimental studies.7,8,21Carvedilol is a nonselective -receptor antagonist that alsoblocks 1-receptors and, unlike other beta-blockers, exerts antioxidanteffects, which may contribute to its actions in heart failure.22,23,24This report summarizes the effects of carvedilol on survivaland on hospitalization for cardiovascular causes.
Methods
Study Patients
All patients in the study had had symptoms of heart failurefor at least three months and had ejection fractions 0.35, despiteat least two months of treatment with diuretics and an angiotensin-converting–enzymeinhibitor (if tolerated); treatment with digoxin, hydralazine,or nitrates was permitted but not required. Patients were excludedfrom the trial if they had had a major cardiovascular eventor had undergone a major surgical procedure within three monthsof entry into the study, or if they had uncorrected, primaryvalvular disease; active myocarditis; sustained ventriculartachycardia or advanced heart block not controlled by antiarrhythmicintervention or a pacemaker; systolic blood pressure of morethan 160 or less than 85 mm Hg or diastolic blood pressure ofmore than 100 mm Hg; a heart rate of less than 68 beats perminute; clinically important hepatic or renal disease; or anycondition other than heart failure that could limit exerciseor survival. Patients receiving calcium-channel blockers, -or -adrenergic agonists or antagonists, or class IC or III antiarrhythmicagents were also not enrolled. The protocol was approved bythe institutional review boards of all 65 participating institutions;written informed consent was obtained from all patients.
Study Procedures
The patients' eligibility was assessed during a three-week screeningperiod, during which exercise capacity was measured by a six-minutecorridor-walk test. Enrollment was stratified into one of fourtreatment protocols on the basis of the patients' performanceon the exercise test. According to the original design, patientsable to walk between 426 and 550 m when tested were assignedto the mild-heart-failure protocol; those able to walk between150 and 425 m were assigned either to the moderate-heart-failureprotocol or to a dose-ranging protocol, depending on the locationof the study center; and those able to walk only less than 150m were assigned to the severe-heart-failure protocol.
After a base-line evaluation, all patients received 6.25 mgof carvedilol twice daily for two weeks (the open-label portionof the study); if this dose was not tolerated, it could be temporarilyreduced to 3.125 mg twice daily and then later increased. Patientswho could tolerate 6.25 mg twice daily were randomly assignedto receive carvedilol or placebo on a double-blind basis, inaddition to their usual medication. The allocation ratio (ofpatients given carvedilol to patients given placebo) was one-to-onein the moderate-heart-failure protocol and two-to-one in themild- and severe-heart-failure protocols; for these patients,the dose of medication was initially 12.5 mg twice daily andwas increased, if tolerated, to 25 to 50 mg twice daily. Patientsassigned to the dose-ranging protocol were randomly assignedto one of four parallel treatment groups (placebo or 6.25 mg,12.5 mg, or 25 mg of carvedilol, twice daily). For all fourprotocols, the dose was gradually adjusted upward to the targetlevel over a period of 2 to 10 weeks, after which double-blindtherapy was maintained for an additional 6 months (except inthe mild-heart-failure protocol, in which patients were treatedfor an additional 12 months). During this time, the patients'other drug therapies for heart failure were kept constant, unlessside effects occurred that were thought to be related eitherto these other medications or to the study drug itself.
Study Objectives and Monitoring
Because of concern that new drugs for heart failure might increasethe risk of death, the sponsors of the program agreed with theFood and Drug Administration in July 1992 to enroll a sufficientnumber of patients in placebo-controlled trials of carvedilolto rule out (with 95 percent confidence) the risk of a 33 percentincrease in mortality with active therapy, assuming an annualmortality rate of 12 percent in the placebo group. As a resultof these discussions, an evaluation of mortality was prospectivelydefined for the present stratified trial program, primarilyfor reasons of safety, with the intent to enroll 1101 patients.However, since it was anticipated (on the basis of earlier studies)that carvedilol could reduce mortality, all statistical analyseswere two-sided. All deaths were classified by investigatorswho had no knowledge of the patients' treatment assignments.In addition, a major secondary objective of each of the componentprotocols was to evaluate the effect of carvedilol on cardiovascularmorbidity, defined as hospitalization for heart failure or othercardiovascular causes.
A data and safety monitoring board was constituted before recruitmentbegan, met periodically to review the unblinded results, andwas empowered to recommend early termination of the programif its members observed a clinically important treatment effect.No formal rules for stopping the trial were adopted before theinitiation of enrollment.
Statistical Analysis
The base-line characteristics of the two treatment groups werecompared with use of the t-test and the chi-square statistic.Cumulative survival curves were constructed as time-to-first-eventplots by Kaplan–Meier survivorship methods,25 and differencesbetween the curves were tested for significance by the log-rankstatistic with use of a Cox proportional-hazards regressionmodel (which included the protocol as a covariate).26 The analysesincluded all randomized patients, and all events were assignedto the patients' original treatment group (on the intention-to-treatprinciple). In the analysis of mortality, data on patients werecensored at the time of cardiac transplantation. Differencesbetween treatment groups in post-randomization measures or eventswere evaluated by analysis of variance and with the chi-squarestatistic. All data are reported as means ±SD.
Results
Randomization began on April 29, 1993, and the study was stoppedearly on the recommendation of the Data and Safety MonitoringBoard on February 3, 1995. This decision was based on the findingof a significant effect of carvedilol on survival — aneffect that exceeded all conventional boundaries used to stopclinical trials.27,28
At the time of the study's early termination, 1197 patientshad entered the open-label, run-in period. Of these, 5.6 percentfailed to complete this period because of adverse events (e.g.,worsening heart failure in 1.4 percent and death in 0.6 percent);another 3.0 percent failed to do so because of violations ofthe protocol or for other administrative reasons. Accordingly,1094 patients were randomly assigned to double-blind treatment:398 with placebo and 696 with carvedilol.
The placebo and carvedilol groups were similar in all pretreatmentcharacteristics (Table 1). After randomization and the adjustmentof dosage, patients received a mean total daily dose of 45±27mg of carvedilol or 60±24 mg of placebo; these doseswere maintained at similar levels throughout the study period.Eighty percent of the patients received target doses of thestudy drugs. The duration of therapy ranged from 1 day to 15.1months (median, 6.5 months). No patient was lost to follow-upwith respect to mortality.
Table 1. Pretreatment Characteristics of Patients in the Study.
Effect of Carvedilol on Survival
In the intention-to-treat analysis, there were 31 deaths (7.8percent) in the placebo group and 22 deaths (3.2 percent) inthe carvedilol group; this difference represents a 65 percentdecrease in the risk of death (95 percent confidence interval,39 to 80 percent; P<0.001) in patients assigned to carvedilol(Figure 1). Treatment with the drug was associated with a largedecrease in the risk of dying of progressive heart failure andin the risk of sudden death (Table 2). The reduction in mortalitydue to carvedilol was similar regardless of age, sex, the causeof heart failure, ejection fraction, exercise tolerance, systolicblood pressure, heart rate, or protocol assignment (Table 3).
Figure 1. Kaplan–Meier Analysis of Survival among Patients with Chronic Heart Failure in the Placebo and Carvedilol Groups.Patients in the carvedilol group had a 65 percent lower risk of death than patients in the placebo group (P<0.001).
Table 3. Effect of Placebo and Carvedilol Treatment on Mortality in Patient Subgroups.
Effect of Carvedilol on Cardiovascular Morbidity
During double-blind therapy, 98 patients (14.1 percent) in thecarvedilol group and 78 patients (19.6 percent) in the placebogroup had at least one hospitalization for cardiovascular causes;this difference represents a 27 percent reduction in the riskof hospitalization (95 percent confidence interval, 3 to 45percent; P = 0.036). To avoid the analytic problem of competingrisks (since patients who have died cannot be hospitalized),the effect of carvedilol on the combined risk of death or hospitalizationfor cardiovascular causes was evaluated with the use of a time-to-first-eventanalysis. As tested for significance with use of the log-ranktest, the combined risk of either dying or being hospitalizedfor cardiovascular reasons was reduced from 24.6 percent inthe placebo group to 15.8 percent in the carvedilol group, a38 percent reduction (95 percent confidence interval, 18 to53 percent; P<0.001) (Figure 2).
Figure 2. Kaplan–Meier Analysis of Survival without Hospitalization for Cardiovascular Reasons (Event-free Survival) in the Placebo and Carvedilol Groups.Patients in the carvedilol group had a 38 percent lower risk of death or hospitalization for cardiovascular disease than patients in the placebo group (P<0.001).
Safety
At the end of double-blind therapy, the mean heart rate decreasedsignificantly more in the carvedilol group than in the placebogroup (by 12.6±12.8 beats per minute vs. 1.4±12.2,P<0.001), although neither group had significant changesin systolic or diastolic blood pressure. Frequently reportedadverse reactions are listed in Table 4; those necessitatingdiscontinuation of the study drug are shown in Table 5. Themost common side effect of carvedilol was dizziness, which occurredduring the initiation of therapy or during the dose-adjustmentperiod but which subsided either spontaneously or after theadjustment of concomitant medications; it did not generallylead to the withdrawal of treatment with the study drug. Themost common reason for the discontinuation of double-blind treatmentwas worsening heart failure, which occurred more frequentlyin the placebo group. Overall, 7.8 percent of the placebo groupand 5.7 percent of the carvedilol group discontinued the studymedication because of adverse reactions; 1.5 percent and 1.1percent, respectively, were withdrawn from the study medicationafter cardiac transplantation. When the program was terminated,more patients were receiving or had completed double-blind treatmentin the carvedilol group than in the placebo group (89 percentvs. 83 percent, P = 0.002).
Table 5. Most Frequent Adverse Reactions Leading to Discontinuation of Double-Blind Treatment.
Discussion
The present report indicates that the addition of carvedilolto conventional therapy is associated with a decrease in mortalityamong patients with chronic heart failure. Patients treatedwith carvedilol had a 65 percent lower risk of death than thosegiven placebo during follow-up that averaged 6.5 months andextended to 15 months. The beneficial effect of carvedilol onsurvival was consistent in all evaluated subgroups and was reflectedin a decrease in the risk of death from progressive heart failureas well as in the risk of sudden death. In addition, carvediloltherapy was associated with a 26 percent reduction in hospitalizationfor cardiovascular causes, a 38 percent decrease in the riskof death or hospitalization, and a lower rate of withdrawalfrom the trial due to worsening heart failure.
Previous controlled studies have shown that beta- blockade canimprove cardiac function, reduce the symptoms of heart failure,improve functional capacity, and enhance exercise tolerance.12,13,14,15,16,17,18,19,20Most of these trials were too small to evaluate the effectsof beta-blockers on morbidity or mortality, but one single-centerstudy with carvedilol18 and two multicenter studies with the1-selective agents metoprolol and bisoprolol19,20 suggestedthat long-term beta-blockade may have favorable effects on thecourse of heart failure. In the single-center study,18 treatmentwith carvedilol for four months reduced the risk of cardiovascularevents. In the two multicenter studies,19,20 treatment withmetoprolol for 12 to 18 months or with bisoprolol for 4 to 44months was associated with fewer hospitalizations for worseningheart failure and a reduced risk of clinical deterioration requiringcardiac transplantation. The decrease in hospitalizations forcardiovascular causes seen with carvedilol in our study reaffirmsthese earlier observations.
Yet previous trials in heart failure have not demonstrated areduction in mortality during beta-blockade. In the two multicenterstudies,19,20 treatment with metoprolol or bisoprolol did notsignificantly decrease the risk of death. One of the trialsretrospectively noted a reduction in mortality only among patientswith nonischemic dilated cardiomyopathy.20 In contrast, in ourstudy, carvedilol therapy was associated with a decrease inmortality, and the benefits of the drug were apparent in allthe subgroups we examined, including patients with underlyingischemic heart disease. The fact that two earlier multicenterstudies did not find an effect on survival may have been relatedto the sample sizes, to the study designs, or to chance. Alternatively,the effects of carvedilol on survival may differ from thoseof other beta-blockers. Unlike metoprolol and bisoprolol, carvedilolblocks both 1- and 2-adrenergic receptors, reduces cardiac norepinephrinelevels, and does not elicit up-regulation of cardiac -receptors.29,30,31Furthermore, unlike other beta-blockers, carvedilol has potentantioxidant effects,24 which may protect against the continuingloss of cardiac myocytes that characterizes the progressionof heart failure.21,32
The initiation of therapy with carvedilol in our study producedside effects consistent with its antiadrenergic actions, butmost of these reactions disappeared — either spontaneouslyor after the adjustment of concomitant medications — anddid not require the discontinuation of double-blind treatment.Thus, most patients were able to tolerate target doses of carvedilol.The most feared side effect of beta-blockade — worseningheart failure during the initiation of therapy — was notan important limitation of treatment; 5.9 percent of the patientshad this side effect during the open-label period, and an additional5.1 percent in the carvedilol group and 4.1 percent in the placebogroup had this reaction after increases in dose during the earlyphases of double-blind therapy. It must be emphasized, however,that carvedilol therapy was initiated in the study with extremecare by physicians experienced in the management of heart failure,who followed specific guidelines that encouraged changes inconcomitant medications to ensure the safety of the patient.Furthermore, our program recruited few patients with New YorkHeart Association class IV heart failure,33 and patients whorequired hospitalization for intravenous drug support were notenrolled. Hence, our study does not allow any conclusions tobe drawn about the safety of carvedilol when it is administeredwithout rigorous supervision or in bedridden patients with advancedheart failure.
To enhance the safety of patients, therapy with carvedilol wasinitiated in small doses that were gradually increased overa period of several weeks. This cautious approach has been followedin studies of other beta-blockers12,13,14,15,16,17,18,19,20,34and is designed to minimize the adverse effects that may occurafter the abrupt withdrawal of the homeostatic support providedby the sympathetic nervous system. Despite such care, however,the frequency of early side effects was expected to be highenough potentially to unblind both the patient and the investigatoras to the treatment-group assignment. To avoid this difficulty,we required patients to complete a two-week, open-label periodbefore randomly assigning them to double-blind therapy; thisdesign feature has been part of many trials studying survivalin heart failure19,35,36 and of all previous controlled trialswith carvedilol. The use of an open-label period not only allowsdrug-related side effects to subside before randomization (thusmaintaining the blindedness of the study) but also enhancesthe study's power, since a trial is less likely to detect atrue effect on survival if patients are randomly assigned totreatment that cannot be maintained for the planned length ofthe study. Although deaths may occur during the open-label period,they cannot be validly assigned to either the treatment or theplacebo group, since they may be related either to the naturalhistory of heart failure or to carvedilol. Fortunately, themortality rate during the two-week, open-label period was low(0.6 percent) and was similar to — if not less than —the rate in the preceding three weeks (1.7 percent), duringwhich patients were being screened for the program but werereceiving only their usual medications for heart failure.
Our findings should be interpreted with the knowledge that thetrial program had several unusual characteristics for a studyof the effect of a drug on survival. Most such trials are designedas long-term studies in which nonfatal events are consideredto be secondary end points. In our program, however, the individualprotocols were designed first to evaluate nonfatal end pointsas components of a single stratified trial program, and thenmortality was specified a priori to assess safety and potentialbenefit. As a result, the duration of follow-up was short andfixed. Although several trials examining mortality in heartfailure have also used a fixed follow-up period,19,37 such adesign necessarily reduces the number of events that can beobserved. This explains why, although the annual mortality inour placebo group (14 to 15 percent) was similar to that inmany studies,35,38 we recorded only 53 deaths (since the averagefollow-up was only 6.5 months). This limited experience restrictsour ability to reach conclusions about the true magnitude orpersistence of any effect on survival. Yet it should be notedthat the number of events during follow-up in our trial wasnot small if morbidity and mortality are combined; 25 percentof the placebo group died or were hospitalized for cardiovascularreasons, and this combined rate was substantially lower in thecarvedilol group. Furthermore, a long follow-up period may notbe possible if the finding of a large treatment effect leadsthe Data and Safety Monitoring Board to recommend early terminationof a study, as occurred in this case; the mean duration of follow-upin the present program was similar to that in other trials thathave been terminated early.36,39,40 Fortunately, long-term dataon carvedilol have recently become available from a trial of415 patients with mild-to-moderate heart failure due to ischemicheart disease who were treated for 18 to 24 months. In thatstudy, carvedilol reduced the combined risk of death or hospitalizationby 26 percent (Sharpe N: personal communication) — a findingsimilar to the 38 percent reduction in mortality and hospitalizationwe observed.
Our finding that carvedilol reduces morbidity and mortalitysupports the hypothesis that a beta-blocker can favorably influencethe course of disease in patients with heart failure. However,because carvedilol exerts pharmacologic effects atypical ofand in addition to its action on adrenergic receptors,22,23,24experience with this drug does not allow us to conclude thatall beta-blockers will favorably alter the natural history ofthis disorder. The question of whether other beta-blockers (suchas metoprolol, bisoprolol, and bucindolol) prolong survivalin heart failure is being addressed in ongoing trials.
Supported by grants from SmithKline Beecham Pharmaceuticalsand Boehringer–Mannheim Therapeutics.
* The U.S. Carvedilol Heart Failure Study Group investigatorsare listed in the Appendix.
Source Information
From the College of Physicians and Surgeons, Columbia University, New York (M.P.); University of Colorado Health Sciences Center, Denver (M.R.B.); University of Minnesota Medical School, Minneapolis (J.N.C.); Boston University School of Medicine, Boston (W.S.C.); Stanford University School of Medicine, Palo Alto, Calif. (M.B.F.); University of Utah School of Medicine, Salt Lake City (E.M.G.); and SmithKline Beecham Pharmaceuticals, King of Prussia, Pa. (N.H.S.).
Address reprint requests to Dr. Packer at the Division of Circulatory Physiology, Columbia University College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032.
References
Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-243. [CrossRef][Medline]
Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823. [Abstract]
Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254. [Abstract]
Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C. [CrossRef][Medline]
Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981;102:210-221. [CrossRef][Medline]
Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804. [Free Full Text]
ver Donck L, Wouters L, Olbrich HG, Mutschler E, Borgers M. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol 1991;18:1-3. [Medline]
Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859. [Free Full Text]
Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;65:20-27.
Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036. [Free Full Text]
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-1376. [Medline]
Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-950.
Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441. [Free Full Text]
Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic -blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642. [Free Full Text]
Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
Metra M, Nardi M, Giubbini R, Cas LD. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506. [Free Full Text]
Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446. [CrossRef][Medline]
CIBIS Investigators and Committees. A randomized trial of -blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773. [Free Full Text]
Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc Res 1992;26:518-525. [Medline]
Ruffolo RR Jr, Gellai M, Heible JP, Willette RN, Nicholas AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:Suppl 2:S82-S88.
Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic effects of carvedilol. Eur Heart J (in press).
Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-98. [Free Full Text]
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556. [CrossRef][Medline]
Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612. [Medline]
Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993;71:23C-29C. [CrossRef][Medline]
Newton GE, Parker JD. 1 vs nonselective -blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation 1995;92:Suppl I:I-395.abstract
Bristow MR, Olsen S, Gilbert EM, et al. -blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart. J Am Coll Cardiol 1992;19:146A-146A.abstract
Dhalla AK, Singh N, Singal PK. Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Circulation 1994;90:I-491.abstract
Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? Circulation 1995;92:Suppl I:I-395.abstract
Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term -blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563. [Free Full Text]
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302. [Abstract]
Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation 1993;88:Suppl I:I-301.abstract
Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155. [Free Full Text]
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552. [Abstract]
The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435. [Abstract]
Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475. [Abstract]
Appendix
The following centers and principal investigators composed theU.S. Carvedilol Heart Failure Study Group: Albuquerque, N.M.— Lovelace Scientific Resources, L. Kuo; Baltimore —Johns Hopkins University Hospital, E. Kasper and A.M. Feldman;Union Memorial Hospital, H. Meilman and D. Goldscher; and Universityof Maryland, S.S. Gottlieb; Beverly Hills, Calif. — CardiovascularResearch Institute of Southern California, R. Karlsburg; Boston— Boston City Hospital, R.H. Falk; Brigham and Women'sHospital, W.S. Colucci and W. Carlson; Massachusetts GeneralHospital, G.W. Dec; and New England Medical Center, J.E. Udelson;Bronx, N.Y. — Albert Einstein College of Medicine, T.H.Le Jemtel; Chapel Hill, N.C. — University of North Carolina,K. Adams; Cleveland— Cleveland Clinic, R. Hobbs; Columbus— Ohio State University Hospital, R.J. Cody; Dallas —University of Texas Southwestern Medical Center, C.W. Yancy;and Veterans Affairs Medical Center (VAMC), E. Eichhorn; Denver— University of Colorado, M.R. Bristow; East Meadow, N.Y.— Nassau County Medical Center, E. Brown and I. Freeman;Elmhurst, N.Y. — Elmhurst Hospital Center, N. Kantrowitz;Falls Church, Va. — INOVA Health System, J. Kiernan, J.O'Brien, and P. Carson; Grosse Pointe, Mich. — Henry FordHealth System and Pierson Clinic, V. Kinhal; Houston —Baylor College of Medicine, J. Young; University of Texas MedicalSchool, G. Schroth and S.E. El Hafi; Jackson — Universityof Mississippi Medical Center, J. O'Connell; Jacksonville —University of Florida, A. Miller; Las Vegas — Heart Instituteof Nevada, J.A. Bowers; Lincoln — Nebraska Heart Institute,S. Krueger; Los Angeles — University of Southern CaliforniaSchool of Medicine, V. DeQuattro; Madison — Universityof Wisconsin School of Medicine, P.S. Rahko; Memphis —University of Tennessee School of Medicine, K.B. Ramanathan;Miami — University of Miami, E. deMarchena; Mineola, N.Y.— Cardiovascular Medical Associates, M. Goodman; and WinthropUniversity Hospital, R. Steingart; Minneapolis — Universityof Minnesota Medical School, S. Kubo and J.N. Cohn; Nashville— Vanderbilt University Medical Center, J.R. Wilson andT.-K. Yeoh; New Haven, Conn. — Yale University Schoolof Medicine, F. Lee; New York — Columbia–PresbyterianMedical Center, J. Sackner-Bernstein, G. W. Neuberg, and M.Packer; Mount Sinai Medical Center, M. Kukin; and St. Luke's–RooseveltMedical Center, M. Klapholz; Northport, N.Y. — VAMC, G.Mallis; Oklahoma City — University of Oklahoma and VAMC,U. Thadani; Park Ridge, Ill. — Lutheran General Hospital,R.P. Sorkin; Philadelphia — Temple University Hospital,I. Pina; Phoenix, Ariz. — Carl T. Hayden VAMC, J.V. Felicetta;Pittsburgh — Presbyterian University Hospital, B. Uretskyand S. Murali; and Western Pennsylvania Hospital, A. Gradman;Portland — Oregon Health Sciences Center, R. Hershberger;Richmond — Medical College of Virginia, G.W. Vetrovec;Rochester, Minn. — Mayo Medical School, L.J. Olson; Rochester,N.Y. — University of Rochester Medical Center, C.-S. Liang;Salt Lake City — University of Utah, E.M. Gilbert; SanDiego, Calif. — Cardiology Associates Medical Group ofEast San Diego, L. Yellen; and Sharp Rees–Stealy MedicalCenter, H. Ingersoll; San Francisco — California PacificMedical Center, S. Woodley; and VAMC, B.M. Massie; Sellersville,Pa. — Buxmont Cardiology Associates, M. Greenspan; St.Louis — St. Louis University Medical Center, L.W. Miller,S.H. Jennison, A.J. Lonigro, and H. Stratman; Stanford, Calif.— Stanford University School of Medicine, M.B. Fowler;Summit, N.J. — Overlook Hospital, J.J. Gregory; Torrance,Calif. — Harbor–UCLA Medical Center, K.A. Narahara;Tucson — University of Arizona Medical Center, S. Butman;Washington, D.C. — Georgetown University Hospital, D.Pearle; Winston-Salem, N.C. — Bowman Gray School of Medicine,F. Kahl; and Worcester — University of Massachusetts MedicalCenter, L. Heller.
Committee members were as follows: Executive Committee —M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler,and E.M. Gilbert; Data and Safety Monitoring Board — A.M.Katz (chair), T. Bashore, C.E. Davis, and P. Kowey; Biostatistics— J. Hosking and S.T. Young; and Study Operations andMonitoring — N.H. Shusterman, M.A. Lukas, A. Flagg, T.Holcslaw, and L.G. Parchman.
Digoxin in Patients with Heart Failure
Umans V. A., Cornel J. H., Hic C., Soto J., Avendaño C., Vilchez F. G., Böhm M., Zoneraich S., Yusuf S., Gorlin R., Garg R., Packer M.
Extract |
Full Text
N Engl J Med 1997;
337:129-131, Jul 10, 1997.
Correspondence
This article has been cited by other articles:
Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., Butler, J.
(2009). The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.. J Am Coll Cardiol
54: 1747-1762
[Abstract][Full Text]
Zhang, Y., Popovic, Z. B., Bibevski, S., Fakhry, I., Sica, D. A., Van Wagoner, D. R., Mazgalev, T. N.
(2009). Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing Model. Circ Heart Fail
2: 692-699
[Abstract][Full Text]
Clark, A. L., Lammiman, M. J., Goode, K., Cleland, J. G.F.
(2009). Is taking part in clinical trials good for your health? A cohort study. Eur J Heart Fail
11: 1078-1083
[Abstract][Full Text]
Zheng, H., Li, Y.-F., Wang, W., Patel, K. P.
(2009). Enhanced angiotensin-mediated excitation of renal sympathetic nerve activity within the paraventricular nucleus of anesthetized rats with heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol.
297: R1364-R1374
[Abstract][Full Text]
Sperandio, P. A., Borghi-Silva, A., Barroco, A., Nery, L. E., Almeida, D. R., Neder, J. A.
(2009). Microvascular oxygen delivery-to-utilization mismatch at the onset of heavy-intensity exercise in optimally treated patients with CHF. Am. J. Physiol. Heart Circ. Physiol.
297: H1720-H1728
[Abstract][Full Text]
Jennings, D. L, Thompson, M. L
(2009). Use of Combination Therapy with a {beta}-Blocker and Milrinone in Patients with Advanced Heart Failure. The Annals of Pharmacotherapy
43: 1872-1876
[Abstract][Full Text]
Zhan, D.-Y., Morimoto, S., Du, C.-K., Wang, Y.-Y., Lu, Q.-W., Tanaka, A., Ide, T., Miwa, Y., Takahashi-Yanaga, F., Sasaguri, T.
(2009). Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. Cardiovasc Res
84: 64-71
[Abstract][Full Text]
Jondeau, G., Neuder, Y., Eicher, J.-C., Jourdain, P., Fauveau, E., Galinier, M., Jegou, A., Bauer, F., Trochu, J. N., Bouzamondo, A., Tanguy, M.-L., Lechat, P., for the B-CONVINCED Investigators,
(2009). B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J
30: 2186-2192
[Abstract][Full Text]
Dorn, G. W. II, Liggett, S. B.
(2009). Mechanisms of Pharmacogenomic Effects of Genetic Variation within the Cardiac Adrenergic Network in Heart Failure. Mol. Pharmacol.
76: 466-480
[Abstract][Full Text]
Hsich, E. M., Pina, I. L.
(2009). Heart failure in women: a need for prospective data.. J Am Coll Cardiol
54: 491-498
[Abstract][Full Text]
Klapholz, M.
(2009). {beta}-Blocker Use for the Stages of Heart Failure. Mayo Clin Proc.
84: 718-729
[Abstract][Full Text]
Schofer, J., Siminiak, T., Haude, M., Herrman, J. P., Vainer, J., Wu, J. C., Levy, W. C., Mauri, L., Feldman, T., Kwong, R. Y., Kaye, D. M., Duffy, S. J., Tubler, T., Degen, H., Brandt, M. C., Van Bibber, R., Goldberg, S., Reuter, D. G., Hoppe, U. C.
(2009). Percutaneous Mitral Annuloplasty for Functional Mitral Regurgitation: Results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation
120: 326-333
[Abstract][Full Text]
Baliga, V., Sapsford, R.
(2009). Review article: Diabetes mellitus and heart failure -- an overview of epidemiology and management. Diabetes and Vascular Disease Research
6: 164-171
[Abstract]
Bansal, S., Lindenfeld, J., Schrier, R. W.
(2009). Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist?. Circ Heart Fail
2: 370-376
[Abstract][Full Text]
De Silva, K., Katbamna, R.
(2009). Principles of heart failure. InnovAiT
2: 423-429
[Abstract][Full Text]
McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., Armstrong, P. W.
(2009). Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. ANN INTERN MED
150: 784-794
[Abstract][Full Text]
Murai, H., Takamura, M., Maruyama, M., Nakano, M., Ikeda, T., Kobayashi, D., Otowa, K.-i., Ootsuji, H., Okajima, M., Furusho, H., Takata, S., Kaneko, S.
(2009). Altered firing pattern of single-unit muscle sympathetic nerve activity during handgrip exercise in chronic heart failure. J. Physiol.
587: 2613-2622
[Abstract][Full Text]
Krum, H.
(2009). Consider {beta} blockers for patients with heart failure. BMJ
338: b1728-b1728
[Full Text]
Dekkers, O M, Elm, E v., Algra, A, Romijn, J A, Vandenbroucke, J P
(2009). How to assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol
0: dyp174v1-dyp174
[Abstract][Full Text]
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W.
(2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol
53: e1-e90
[Full Text]
Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W.
(2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol
53: 1343-1382
[Full Text]
2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, , Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W.
(2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation
119: 1977-2016
[Full Text]
2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W.
(2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation
119: e391-e479
[Full Text]
Calvert, M. J, Shankar, A., McManus, R. J, Ryan, R., Freemantle, N.
(2009). Evaluation of the management of heart failure in primary care. Fam Pract
26: 145-153
[Abstract][Full Text]
Shen, J.-B., Shutt, R., Agosto, M., Pappano, A., Liang, B. T.
(2009). Reversal of cardiac myocyte dysfunction as a unique mechanism of rescue by P2X4 receptors in cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol.
296: H1089-H1095
[Abstract][Full Text]
Stamato, N. J.
(2009). On being critical of implantable cardioverter-defibrillator therapy.. J Am Coll Cardiol
53: 1162-1162
[Full Text]
Cleland, J. G.F., Cullington, D.
(2009). Digoxin: Quo Vadis?. Circ Heart Fail
2: 81-85
[Full Text]
Erdmann, E.
(2009). Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl
11: A21-A25
[Abstract][Full Text]
Willenheimer, R.
(2009). The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial. Eur Heart J Suppl
11: A15-A20
[Abstract][Full Text]
Anand, I. S., Carson, P., Galle, E., Song, R., Boehmer, J., Ghali, J. K., Jaski, B., Lindenfeld, J., O'Connor, C., Steinberg, J. S., Leigh, J., Yong, P., Kosorok, M. R., Feldman, A. M., DeMets, D., Bristow, M. R.
(2009). Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients With Advanced Heart Failure: Results From the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial. Circulation
119: 969-977
[Abstract][Full Text]
Hernandez, A. F., Hammill, B. G., O'Connor, C. M., Schulman, K. A., Curtis, L. H., Fonarow, G. C.
(2009). Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.. J Am Coll Cardiol
53: 184-192
[Abstract][Full Text]
Lewin, G., Matus, M., Basu, A., Frebel, K., Rohsbach, S. P., Safronenko, A., Seidl, M. D., Stumpel, F., Buchwalow, I., Konig, S., Engelhardt, S., Lohse, M. J., Schmitz, W., Muller, F. U.
(2009). Critical Role of Transcription Factor Cyclic AMP Response Element Modulator in {beta}1-Adrenoceptor-Mediated Cardiac Dysfunction. Circulation
119: 79-88
[Abstract][Full Text]
McMurray, J., Petrie, M., Swedberg, K., Komajda, M., Anker, S., Gardner, R.
(2009). CHAPTER 23 Heart Failure. ESC Textbook of Cardiovascular Medicine
2: med-9780199566990-chapter-med-9780199566990-chapter
[Abstract][Full Text]
Go, A. S., Yang, J., Gurwitz, J. H., Hsu, J., Lane, K., Platt, R.
(2008). Comparative Effectiveness of Different {beta}-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice. Arch Intern Med
168: 2415-2421
[Abstract][Full Text]
Kramer, J. M., Curtis, L. H., Dupree, C. S., Pelter, D., Hernandez, A., Massing, M., Anstrom, K. J.
(2008). Comparative Effectiveness of {beta}-Blockers in Elderly Patients With Heart Failure. Arch Intern Med
168: 2422-2428
[Abstract][Full Text]
Pitt, B.
(2008). Comparative Effectiveness of {beta}-Blockers in Elderly Patients With Heart Failure--Invited Commentary. Arch Intern Med
168: 2431-2432
[Full Text]
Curtis, L. H., Greiner, M. A., Hammill, B. G., Kramer, J. M., Whellan, D. J., Schulman, K. A., Hernandez, A. F.
(2008). Early and Long-term Outcomes of Heart Failure in Elderly Persons, 2001-2005. Arch Intern Med
168: 2481-2488
[Abstract][Full Text]
Holubarsch, C. J.F., Colucci, W. S., Meinertz, T., Gaus, W., Tendera, M., Survival and Prognosis: Investigation of Crataegus,
(2008). The efficacy and safety of Crataegus extract WS(R) 1442 in patients with heart failure: The SPICE trial. Eur J Heart Fail
10: 1255-1263
[Abstract][Full Text]
Pasquali, S. K., Hall, M., Slonim, A. D., Jenkins, K. J., Marino, B. S., Cohen, M. S., Shah, S. S.
(2008). Off-Label Use of Cardiovascular Medications in Children Hospitalized With Congenital and Acquired Heart Disease. Circ Cardiovasc Qual Outcomes
1: 74-83
[Abstract][Full Text]
Mehta, P. A., Dubrey, S. W., McIntyre, H. F., Walker, D. M., Hardman, S. M.C., Sutton, G. C., McDonagh, T. A., Cowie, M. R.
(2008). Mode of death in patients with newly diagnosed heart failure in the general population. Eur J Heart Fail
10: 1108-1116
[Abstract][Full Text]
Tribouilloy, C, Rusinaru, D, Mahjoub, H, Tartiere, J-M, Kesri-Tartiere, L, Godard, S, Peltier, M
(2008). Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart
94: 1450-1455
[Abstract][Full Text]
Johnson, J. A.
(2008). Ethnic Differences in Cardiovascular Drug Response: Potential Contribution of Pharmacogenetics. Circulation
118: 1383-1393
[Full Text]
Remme, W. J., McMurray, J. J.V., Hobbs, F.D. R., Cohen-Solal, A., Lopez-Sendon, J., Boccanelli, A., Zannad, F., Rauch, B., Keukelaar, K., Macarie, C., Ruzyllo, W., Cline, C., for the SHAPE Study Group,
(2008). Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J
29: 1739-1752
[Abstract][Full Text]
Nishii, M., Inomata, T., Takehana, H., Naruke, T., Yanagisawa, T., Moriguchi, M., Takeda, S., Izumi, T.
(2008). Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.. J Am Coll Cardiol
51: 2329-2335
[Abstract][Full Text]
Couchonnal, L. F., Anderson, M. E.
(2008). The Role of Calmodulin Kinase II in Myocardial Physiology and Disease. Physiology
23: 151-159
[Abstract][Full Text]
Moye, L. A
(2008). Disciplined analyses in clinical trials: the dark heart of the matter. Stat Methods Med Res
17: 253-264
[Abstract]
Kasama, S., Toyama, T., Sumino, H., Nakazawa, M., Matsumoto, N., Sato, Y., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M.
(2008). Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. JNM
49: 907-914
[Abstract][Full Text]
Beer, M., Wagner, D., Myers, J., Sandstede, J., Kostler, H., Hahn, D., Neubauer, S., Dubach, P.
(2008). Effects of Exercise Training on Myocardial Energy Metabolism and Ventricular Function Assessed by Quantitative Phosphorus-31 Magnetic Resonance Spectroscopy and Magnetic Resonance Imaging in Dilated Cardiomyopathy. J Am Coll Cardiol
51: 1883-1891
[Abstract][Full Text]
Eisen, H. J.
(2008). Exercise Training and Myocardial Energetics in Patients With Heart Failure: When More Is Less. J Am Coll Cardiol
51: 1892-1895
[Full Text]
Nishio, M., Sakata, Y., Mano, T., Ohtani, T., Takeda, Y., Miwa, T., Hori, M., Masuyama, T., Kondo, T., Yamamoto, K.
(2008). Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail
10: 446-453
[Abstract][Full Text]
Hansen, M. L., Gadsboll, N., Gislason, G. H., Abildstrom, S. Z., Schramm, T. K., Folke, F., Friberg, J., Sorensen, R., Rasmussen, S., Poulsen, H. E., Kober, L., Madsen, M., Torp-Pedersen, C.
(2008). Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace
10: 395-402
[Abstract][Full Text]
Chupp, G. L.
(2008). Say What, Beta-Blockers for Asthma?. Am. J. Respir. Cell Mol. Bio.
38: 249-250
[Full Text]
Fantoni, C., Regoli, F., Ghanem, A., Raffa, S., Klersy, C., Sorgente, A., Faletra, F., Baravelli, M., Inglese, L., Salerno-Uriarte, J. A., Klein, H. U., Moccetti, T., Auricchio, A.
(2008). Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail
10: 298-307
[Abstract][Full Text]
Xu-Cai, Y. O., Brotman, D. J., Phillips, C. O., Michota, F. A., Tang, W. H. W., Whinney, C. M., Panneerselvam, A., Hixson, E. D., Garcia, M., Francis, G. S., Jaffer, A. K.
(2008). Outcomes of Patients With Stable Heart Failure Undergoing Elective Noncardiac Surgery. Mayo Clin Proc.
83: 280-288
[Abstract][Full Text]
Albert, N. M.
(2007). Switching to Once-Daily Evidence-Based -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction. Crit Care Nurse
27: 62-72
[Full Text]
Buettner, H. J., Mueller, C.
(2007). Effects of obesity on mortality in patients with unstable angina or non-ST-elevation myocardial infarction: reply. Eur Heart J
28: 2950-2951
[Full Text]
Remme, W. J.
(2007). Filling the gap between guidelines and clinical practice in heart failure treatment -- Still a far cry from reality. Eur J Heart Fail
9: 1143-1145
[Full Text]
Triller, D. M., Hamilton, R. A.
(2007). Effect of pharmaceutical care services on outcomes for home care patients with heart failure. Am J Health Syst Pharm
64: 2244-2249
[Abstract][Full Text]
Remme, W. J., Cleland, J. G., Erhardt, L., Spark, P., Torp-Pedersen, C., Metra, M., Komajda, M., Moullet, C., Lukas, M. A., Poole-Wilson, P., Di Lenarda, A., Swedberg, K.
(2007). Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail
9: 1128-1135
[Abstract][Full Text]
Fauchier, L., Pierre, B., de Labriolle, A., Babuty, D.
(2007). Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: A meta-analysis of randomised controlled trials. Eur J Heart Fail
9: 1136-1139
[Abstract][Full Text]
Tsukamoto, T., Morita, K., Naya, M., Inubushi, M., Katoh, C., Nishijima, K., Kuge, Y., Okamoto, H., Tsutsui, H., Tamaki, N.
(2007). Decreased Myocardial {beta}-Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. JNM
48: 1777-1782
[Abstract][Full Text]
Schwartz, P. J., Vanoli, E.
(2007). From exercise training to sudden death prevention via adrenergic receptors. Am. J. Physiol. Heart Circ. Physiol.
293: H2631-H2633
[Full Text]
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., Lefkowitz, R. J.
(2007). A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. USA
104: 16657-16662
[Abstract][Full Text]
Okumura, S., Vatner, D. E., Kurotani, R., Bai, Y., Gao, S., Yuan, Z., Iwatsubo, K., Ulucan, C., Kawabe, J.-i., Ghosh, K., Vatner, S. F., Ishikawa, Y.
(2007). Disruption of Type 5 Adenylyl Cyclase Enhances Desensitization of Cyclic Adenosine Monophosphate Signal and Increases Akt Signal With Chronic Catecholamine Stress. Circulation
116: 1776-1783
[Abstract][Full Text]
Shaddy, R. E., Boucek, M. M., Hsu, D. T., Boucek, R. J., Canter, C. E., Mahony, L., Ross, R. D., Pahl, E., Blume, E. D., Dodd, D. A., Rosenthal, D. N., Burr, J., LaSalle, B., Holubkov, R., Lukas, M. A., Tani, L. Y., For the Pediatric Carvedilol Study Group,
(2007). Carvedilol for Children and Adolescents With Heart Failure: A Randomized Controlled Trial. JAMA
298: 1171-1179
[Abstract][Full Text]
Gidding, S. S.
(2007). The Importance of Randomized Controlled Trials in Pediatric Cardiology. JAMA
298: 1214-1216
[Full Text]
Metra, M., Torp-Pedersen, C., Cleland, J. G.F., Di Lenarda, A., Komajda, M., Remme, W. J., Cas, L. D., Spark, P., Swedberg, K., Poole-Wilson, P. A., for the COMET investigators,
(2007). Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail
9: 901-909
[Abstract][Full Text]
Gustafsson, F., Schou, M., Videbaek, L., Nielsen, T., Ulriksen, H., Markenvard, J., Svendsen, T. L., Ryde, H., Vigholt, E., Hildebrandt, P., on behalf of the Danish Heart Failure Clinics Netw,
(2007). Treatment with beta-blockers in nurse-led heart failure clinics: Titration efficacy and predictors of failure. Eur J Heart Fail
9: 910-916
[Abstract][Full Text]
Swedberg, K.
(2007). Pure heart rate reduction: further perspectives in heart failure. Eur Heart J Suppl
9: F20-F24
[Abstract][Full Text]
Agostoni, P., Contini, M., Cattadori, G., Apostolo, A., Sciomer, S., Bussotti, M., Palermo, P., Fiorentini, C.
(2007). Lung function with carvedilol and bisoprolol in chronic heart failure: Is {beta} selectivity relevant?. Eur J Heart Fail
9: 827-833
[Abstract][Full Text]
Colucci, W. S., Kolias, T. J., Adams, K. F., Armstrong, W. F., Ghali, J. K., Gottlieb, S. S., Greenberg, B., Klibaner, M. I., Kukin, M. L., Sugg, J. E., on behalf of the REVERT Study Group,
(2007). Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial. Circulation
116: 49-56
[Abstract][Full Text]
Patel, J., Heywood, J. T.
(2007). Mode of Death in Patients With Systolic Heart Failure. J CARDIOVASC PHARMACOL THER
12: 127-136
[Abstract]
Fedoruk, L. M., Tribble, C. G., Kern, J. A., Peeler, B. B., Kron, I. L.
(2007). Predicting Operative Mortality After Surgery for Ischemic Cardiomyopathy. Ann. Thorac. Surg.
83: 2029-2035
[Abstract][Full Text]
Matus, M., Lewin, G., Stumpel, F., Buchwalow, I. B., Schneider, M. D., Schutz, G., Schmitz, W., Muller, F. U.
(2007). Cardiomyocyte-specific inactivation of transcription factor CREB in mice. FASEB J.
21: 1884-1892
[Abstract][Full Text]
Johnson, M. J
(2007). Management of end stage cardiac failure. Postgrad. Med. J.
83: 395-401
[Abstract][Full Text]
Cheng, Y., George, I., Yi, G.-H., Reiken, S., Gu, A., Tao, Y. K., Muraskin, J., Qin, S., He, K.-L., Hay, I., Yu, K., Oz, M. C., Burkhoff, D., Holmes, J., Wang, J.
(2007). Bradycardic Therapy Improves Left Ventricular Function and Remodeling in Dogs with Coronary Embolization-Induced Chronic Heart Failure. J. Pharmacol. Exp. Ther.
321: 469-476
[Abstract][Full Text]
Gentile, C. L., Orr, J. S., Davy, B. M., Davy, K. P.
(2007). Modest weight gain is associated with sympathetic neural activation in nonobese humans. Am. J. Physiol. Regul. Integr. Comp. Physiol.
292: R1834-R1838
[Abstract][Full Text]
Kasama, S., Toyama, T., Hatori, T., Sumino, H., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M.
(2007). Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J
0: ehm048v1-7
[Abstract][Full Text]
Frazier, C. G., Alexander, K. P., Newby, L. K., Anderson, S., Iverson, E., Packer, M., Cohn, J., Goldstein, S., Douglas, P. S.
(2007). Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction: A Pooled Analysis of 5 Randomized Control Trials. J Am Coll Cardiol
49: 1450-1458
[Abstract][Full Text]
Hauptman, P. J., Sabbah, H. N.
(2007). Reversal of ventricular remodeling: Important to establish and difficult to define. Eur J Heart Fail
9: 325-328
[Full Text]
Berry, C., Murphy, N., De Vito, G., Galloway, S., Seed, A., Fisher, C., Sattar, N., Vallance, P., Hillis, W. S., McMurray, J.
(2007). Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail
9: 429-434
[Abstract][Full Text]
Neubauer, S.
(2007). The Failing Heart -- An Engine Out of Fuel. NEJM
356: 1140-1151
[Full Text]
Allen, L. A., O'Connor, C. M.
(2007). Management of acute decompensated heart failure. CMAJ
176: 797-805
[Abstract][Full Text]
Remme, W. J., Torp-Pedersen, C., Cleland, J. G.F., Poole-Wilson, P. A., Metra, M., Komajda, M., Swedberg, K., Di Lenarda, A., Spark, P., Scherhag, A., Moullet, C., Lukas, M. A.
(2007). Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure: Results From COMET. J Am Coll Cardiol
49: 963-971
[Abstract][Full Text]
0.35 were randomly assigned to receive either placebo (n = 398) or the beta-blocker carvedilol (n = 696); background therapy with digoxin, diuretics, and an angiotensin-converting–enzyme inhibitor remained constant. Patients were observed for the occurrence of death or hospitalization for cardiovascular reasons during the following 6 months (12 months for the group with mild heart failure). 
-receptor antagonist that also blocks 
1-receptors and, unlike other beta-blockers, exerts antioxidant effects, which may contribute to its actions in heart failure.22,23,24 This report summarizes the effects of carvedilol on survival and on hospitalization for cardiovascular causes. 
